SCHEMBL801295

SCHEMBL801295

CCOC(=O)Cc1ccc(C(=O)/C=C/N(C)C)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
ALDH1A1 P00352 7/20 0.62
RAB9A P51151 5/20 0.62
NPC1 O15118 3/20 0.62
KMT2A Q03164 2/20 0.62
HPGD P15428 2/20 0.54
LMNA P02545 7/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
RECQL P46063 2/20 0.53
ALOX12 P18054 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.50
POLB P06746 3/20 0.50
MEN1 O00255 1/20 0.50
HSP90AA1 P07900 1/20 0.50
HTT P42858 2/20 0.49
CYP4Z1 Q86W10 1/20 0.47
GAA P10253 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933205 0.82 ATG4B (0.56) MAPTALDH1A1KMT2AHPGDLMNA
SCHEMBL4933202 0.82 ATG4B (0.56) MAPTALDH1A1KMT2AHPGDLMNA
SCHEMBL4070316 0.82 MAPT (0.60) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4070320 0.82 MAPT (0.60) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL11462210 0.80 MAPT (0.76) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL11462209 0.80 MAPT (0.76) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL10958212 0.79 THRB (0.58) MAPTALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL15183943 0.79 MAPT (0.69) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL8312404 0.78 MAPT (0.64) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL23251385 0.78 MAPT (0.81) MAPTALDH1A1RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071523-A1 BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS PDF, EIF5B, EIF4E MAPT 3128/4885ALDH1A1 3464/4885RAB9A 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.